G

GI Innovation Inc
KOSDAQ:358570

Watchlist Manager
GI Innovation Inc
KOSDAQ:358570
Watchlist
Price: 10 030 KRW -4.11% Market Closed
Market Cap: 443.5B KRW
Have any thoughts about
GI Innovation Inc?
Write Note

P/FCFE
Price to FCFE

-11.9
Current
-12
Median
25.2
Industry
Higher than median
Lower than industry value

Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.

P/FCFE
-11.9
=
Market Cap
443.3B KRW
/
FCFE
-37.4B KRW
All Countries
Close
Market Cap P/FCFE
KR
GI Innovation Inc
KOSDAQ:358570
443.3B KRW -11.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -3 227 395.3
US
Abbvie Inc
NYSE:ABBV
312.7B USD 12.5
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 26.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD -87.6
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 11.2
US
Epizyme Inc
F:EPE
94.1B EUR -425.2
AU
CSL Ltd
ASX:CSL
133.6B AUD 79
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 24.9
US
Seagen Inc
F:SGT
39.3B EUR -58.5
NL
argenx SE
XBRU:ARGX
34.5B EUR -108.8
 
KR
G
GI Innovation Inc
KOSDAQ:358570
Average P/FCFE: 30.9
Negative Multiple: -11.9
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -3 227 395.3
US
Abbvie Inc
NYSE:ABBV
12.5
US
Amgen Inc
NASDAQ:AMGN
26.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -87.6
US
Gilead Sciences Inc
NASDAQ:GILD
11.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -425.2
AU
CSL Ltd
ASX:CSL
79
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
24.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.5
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.8

P/FCFE Forward Multiples

Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A

See Also

Discover More